Vigorous Steve retatrutide explained: what the fitness YouTuber says about dosing, side effects, and how this investigational triple agonist compares.
Vigorous Steve has covered retatrutide as a potent but unapproved weight-loss drug, and his videos focus on the science, the trial doses, the side effects, and why bodybuilders are curious about it for appetite control. He frames vigorous steve retatrutide discussion as research first, use later, if at all. The short version: retatrutide is an investigational triple agonist that is not FDA-approved for human use in the United States.
Who Vigorous Steve Is and Why His Retatrutide Take Gets Attention
Vigorous Steve is a longtime bodybuilding and fitness YouTuber known for long-form videos on peptides, performance drugs, bloodwork, and harm reduction. His audience skews toward experienced lifters who already read studies and want a translator between the research and the gym.
Two things shape how he talks about retatrutide:
- He leans on published data. Doses, trial phases, and adverse events get cited rather than guessed.
- He is not a physician. His channel is educational commentary, and he repeats that disclaimer. Nothing he publishes should be treated as a prescription or a personal medical recommendation.
What Retatrutide Actually Is
Retatrutide is an investigational triple agonist developed by Eli Lilly that activates three receptors at once: GLP-1, GIP, and glucagon. The GLP-1 and GIP arms drive appetite suppression and improved glucose control, while the glucagon arm appears to raise energy expenditure.
That third receptor is what separates retatrutide from every approved weight-loss drug on the US market. It is still being studied in Phase 3 trials, which means researchers are continuing to collect the safety and efficacy data regulators require.
Retatrutide is not FDA-approved for any human use in the United States. That single fact drives most of the caution in Vigorous Steve's commentary.
The Retatrutide Points Vigorous Steve Emphasizes
Dosing in the Trials
In the Phase 2 trial, participants started low and titrated upward every four weeks to blunt gastrointestinal side effects. Weekly doses ranged from 1 mg to 12 mg.
| Weekly dose (Phase 2) | Average weight loss at 48 weeks |
|---|---|
| 1 mg | About 8.7% |
| 4 mg | About 17.1% |
| 8 mg | About 22.8% |
| 12 mg | About 24.2% |
These are group averages from a controlled trial, not a promise of what any individual will experience.
Side Effects and Lean Mass
The most commonly reported issues in trials are gastrointestinal, and they tend to ease after each dose increase. Common complaints include:
- Nausea, vomiting, diarrhea, and constipation
- Small increases in resting heart rate
- Injection site reactions
- Appetite suppression strong enough to make protein targets hard to hit
The lean-mass question matters most for bodybuilders. Rapid weight loss usually includes some muscle, and Vigorous Steve's recurring advice is to keep protein high, keep training heavy, and avoid crash deficits.
Sourcing, Reconstitution, and Storage
Because retatrutide is unapproved, it is not sold in pharmacies. Most people who encounter it are dealing with research-chemical vials of unknown purity, which is a very different risk category than a prescription drug.
Reconstitution questions dominate forums, and even basics like how much bac water for 10 mg retatrutide get passed around without a standard answer, since there is no approved protocol to copy. Storage is another gray area: how long does retatrutide last after adding bac water depends on refrigeration, handling, and the assumptions of whoever is answering.
How Retatrutide Compares With Approved Drugs
Searches for retatrutide vs tirzepatide which is better usually come down to trial numbers, because both drugs hit GLP-1 and GIP. Retatrutide adds the glucagon receptor, and early data hint at slightly greater average weight loss, but tirzepatide is approved and retatrutide is not.
| Drug | Receptors | FDA status | Weekly dose | Average weight loss in trials |
|---|---|---|---|---|
| Semaglutide (Wegovy) | GLP-1 | Approved | 2.4 mg | About 15% at 68 weeks |
| Tirzepatide (Zepbound) | GIP + GLP-1 | Approved | 5–15 mg | About 21% at 72 weeks |
| Retatrutide | GLP-1 + GIP + glucagon | Investigational | 1–12 mg in trials | About 24% at 48 weeks |
Cross-trial comparisons are imperfect. Different populations, durations, and titration schedules mean only a head-to-head trial can settle which drug is more effective.
Where AOD 9604 Enters the Conversation
aod 9604 vs retatrutide is a comparison of two very different tools. AOD 9604 is a fragment of human growth hormone studied for fat oxidation, with a modest and inconsistent effect on body weight. Retatrutide works through appetite and satiety signaling, which is why its weight-loss numbers are an order of magnitude larger.
There is no published human trial data on using aod 9604 with retatrutide together, so anyone stacking them is experimenting without a safety map.
Safety, Legality, and Sensible Next Steps
Retatrutide cannot legally be prescribed in the United States today. Approved GLP-1 options do exist, and a licensed clinician can help you weigh them against your health history.
- Talk to a healthcare professional before starting any GLP-1 class drug.
- Ask about baseline bloodwork, dosing, and how to manage gastrointestinal side effects.
- Be skeptical of any vendor selling retatrutide as a finished product for human use.
Vigorous Steve's videos are useful for understanding the pharmacology. They are not a substitute for a doctor who knows your history.
Bottom Line
Vigorous Steve treats retatrutide as the most potent investigational weight-loss drug in the GLP-1 era, and as something to approach with data rather than hype. The drug is unapproved, the long-term safety picture is incomplete, and the sourcing risk is real.
If you want the effect today, approved options plus medical supervision are the safer path. If you want to understand the science, long-form breakdowns are a reasonable starting point as long as you keep the caveats attached.
Frequently Asked Questions
What does Vigorous Steve say about retatrutide?
He describes it as a potent triple agonist that is not FDA-approved, and he focuses on mechanism, trial dosing, side effects, and sourcing risks rather than promoting use. His channel frames retatrutide as a research compound for informed adults, and he repeats that his content is educational commentary rather than medical advice.
Is retatrutide FDA-approved for weight loss?
No. Retatrutide is still in Phase 3 clinical trials and is not approved by the FDA for any indication. It cannot be legally prescribed in the United States, and products sold online as retatrutide are unregulated research chemicals of unknown purity.
What dose of retatrutide was used in clinical trials?
The Phase 2 trial tested once-weekly doses of 1 mg, 4 mg, 8 mg, and 12 mg, with participants titrating up every four weeks. Higher doses produced greater average weight loss but also more gastrointestinal side effects. Dosing discussions on channels like Vigorous Steve's reference these trial numbers rather than one personal protocol.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.